affiliate disclosure · we earn commission on some vendor links. audits, scores, and rankings are independent — vendors do not pay for placement. read more →
Is Hims & Hers Health legit?
Hims & Hers Health is operating and surfaces credible public signals (composite 60/100), but we have not placed a first-hand consult yet — this is a public-data audit. The largest 503A telehealth compounder in the GLP-1 space and the most exposed to FDA enforcement on the "personalized" compounding pathway after the 2025 shortage discretion closed. Strong platform UX and pricing transparency, weakened by the regulatory cloud around the post-shortage business model and a mixed buyer-experience signal at scale. The signal table below shows what we verified and what is still open. Read the full audit for FDA history, state-board records, and licensure footprint.
Signal table
WHAT WE VERIFIEDWhat works, what does not
AUDIT SUMMARY- Posts monthly pricing for compounded semaglutide and tirzepatide programs directly on the site, including the trial-month discount and the recurring-subscription rate
- Hims & Hers Health is publicly traded (NYSE - HIMS) which means quarterly SEC filings, audited financials, and earnings-call disclosures are part of the verifiable public record
- Affiliated dispensing pharmacies in the network are FDA-registered 503A facilities under public state-pharmacy-board oversight
- Telehealth intake process is structured and the platform is operationally mature at scale (multi-million customer base)
- State licensure coverage is broad - the platform ships to most US states under its network of affiliated pharmacies
- The "personalized" compounding pathway Hims pivoted to after the FDA shortage discretion closed in 2025 is an active regulatory pressure point. FDA has stated that "personalization" must be tied to specific clinical need, not a marketing pathway around the shortage rule
- The partnership with Novo Nordisk for branded Wegovy was publicly terminated by Novo in mid-2025, citing Hims's continued promotion of compounded versions. This is the most visible public dispute between a brand-name manufacturer and a 503A compounder in the GLP-1 market
- Hims faces ongoing shareholder litigation related to disclosures around the compounded-GLP-1 business after the shortage ended
- The full partner-pharmacy roster is not transparently disclosed at the per-fill level. A buyer does not see which dispensing facility filled their prescription at checkout
- Subscription model with friction on cancellation and refill cadence surfaces repeatedly in Trustpilot and r/Tirzepatidecompound reviews
- Trustpilot rating sits in the mid-3 / low-4 range, materially below the smaller compounders covered in our v0 cohort (Trillium 4.5, Fifty410 4.7)
- API (active pharmaceutical ingredient) sourcing dossier is not publicly disclosed at the upstream-manufacturer level
What we mean by “legit”
SCORING SPINEFor a 503A compounding pharmacy, "legit" is not a single yes-or-no signal. The composite is a weighted average across nine dimensions — state pharmacy licensure footprint, FDA inspection history, state-board enforcement, USP <797> sterility signals, prescriber quality, raw-material sourcing, price transparency, buyer experience, and buyer protection. Read the full rubric at /methodology/compounding.
For Hims & Hers Health the audit is "public-data tier" — we aggregate pharmacy disclosures, FDA databases, state-board records, NPI registry data, and community signals. A first-hand consult is pending and this page will be upgraded when that lands.
Frequently asked
6 QUESTIONSIs Hims & Hers Health legit?
Hims & Hers Health is operating and surfaces credible public signals (composite 60/100), but we have not placed a first-hand consult yet — this is a public-data audit. The largest 503A telehealth compounder in the GLP-1 space and the most exposed to FDA enforcement on the "personalized" compounding pathway after the 2025 shortage discretion closed. Strong platform UX and pricing transparency, weakened by the regulatory cloud around the post-shortage business model and a mixed buyer-experience signal at scale. The signal table below shows what we verified and what is still open. Read the full audit for FDA history, state-board records, and licensure footprint.
Is Hims & Hers Health a real pharmacy?
Hims & Hers Health operates a hybrid model — it both dispenses directly and routes some prescriptions to partner pharmacies. The legal entity is Hims & Hers Health, Inc..
What states is Hims & Hers Health licensed in?
Hims & Hers Health serves all 50 states. You can confirm any state's licensure directly through that state's Board of Pharmacy license-lookup tool.
Has Hims & Hers Health had any FDA inspections?
No FDA actions are on record (public databases as of 2026-05-28) for Hims & Hers Health. Absence of a 483 or warning letter is not the same as a sterility audit — the FDA inspects 503A pharmacies on a complaint-driven and risk-based cycle, not annually.
Has vialaudit placed a consult with Hims & Hers Health?
Not yet. Hims & Hers Health is currently a public-data audit. We aggregate pharmacy disclosures, FDA inspection databases, state-board enforcement records, NPI registry data, and community signals. A first-hand consult is pending — this page upgrades when that lands.
How does Hims & Hers Health compare to other compounding pharmacies?
Hims & Hers Health's composite is 60/100. The composite is weighted across nine dimensions — licensure, FDA history, state enforcement, sterility, prescriber, sourcing, price transparency, buyer experience, and buyer protection. See /pharmacies for the full leaderboard and /methodology/compounding for the rubric.
Verdict
READ FULL AUDIT →Other audited pharmacies
IS IT LEGIT?Sources
8 CITED- Hims & Hers Health homepage — vendor
- Hims & Hers Health - investor relations & SEC filings — company / SEC
- FDA - Compounding under section 503A of the Federal Food, Drug, and Cosmetic Act — FDA
- FDA - Compounding inspections, recalls, and other actions — FDA
- Hims & Hers Health - Trustpilot profile — Trustpilot
- r/tirzepatidecompound May 2026 telehealth & pharmacy survey — Reddit community survey
- vialaudit - Compounded semaglutide in 2026 status read — vialaudit
- vialaudit - 503A and the PCAC GLP-1 compounding article — vialaudit